secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alkermes plc. (ALKS)
CIK:        0001520262
Form:       8-K
Filed at:   2024-02-15T23:59:59+00:00
Accession:  0000950170-24-015597
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alkermes reports 2023 total revenues $1.66B, GAAP EPS $2.10; guides 2024 EBITDA ~$445-485M
--------------------------------------------------------------------------------

- GAAP net income $355.8M vs loss of $158.3M in 2022; diluted EPS $2.10.
- Proprietary net sales $920M (+18% YoY); LYBALVI grew to $191.9M (up 100% YoY).
- 2024 guidance: total rev $1.5-1.6B, GAAP net income $350-390M, non-GAAP net income $465-505M.
- Board approved new $400M share repurchase program (no expiration date).
- Oncology separation completed Nov 2023; Athlone facility sale to Novo Nordisk for $92.5M expected mid-2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1520262/000095017024015597/0000950170-24-015597-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1520262/000095017024015597/alks-20240215.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-015597

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer